Apotex decision has ramifications for drug supply chain

The decision of a large player like Apotex to pull three products from the PBS has ramifications for the whole drug supply chain, says Generic and Biosimilar Medicines Association (GBMA) CEO Belinda Wood.

Apotex last week announced it would remove Paracetamol/codeine tablets 500mg/30mg blister pack 20, Cephalexin suspension 125mg/5mL bottle 100mL and 250mg/5mL bottle 100ml from the scheme, saying it was incurring “sustained losses” on the items as a result